Pediatric Cancers | Topics

In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.

The addition of temozolomide to vincristine and irinotecan appears to be a new standard of care for adult and pediatric patients with relapsed/refractory rhabdomyosarcoma, according to the European Paediatric Soft Tissue Sarcoma Group.

Pediatric patients with medulloblastoma may experience benefit from 177Lu-omburtamab-DTPA, which was granted a rare pediatric disease designation by the FDA.

ASTCT recently published an article in their journal Nucleus detailing CAR T-cell in pediatric patients with brain cancer.

A recent study provides evidence showing that focal 22q11.22 deletions may be correlated with poor outcomes in patients with pediatric B-cell acute lymphoblastic leukemia with alterations in IKZF1.

Pediatric patients with low-risk acute lymphoblastic leukemia may be able to omit treatment with vincristine and dexamethasone pulse therapy after the first year of treatment.

Racial and ethnic disparities in incidence and risk of childhood cancer have been identified across a number of malignancies.

KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.

Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation.

“As the number of AYA survivors continues to grow, there is a pressing need for targeted information, education, and intervention around sexual health, intimate relationships, and body image,” the Children’s Oncology Group (COG) AYA Oncology Discipline Committee wrote in a review.